Pivotal-Point Follow-up Scholar Rock Holding (SRRK): Clinical Breakthrough in Spinal Muscular Atrophy Leads to $25 Million Milestone Payment!

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts. Its focus is on the development of novel therapeutics aimed at the activation of growth factors in the extracellular matrix. The emphasis is on treating diseases with high unmet medical need, particularly spinal muscular atrophy (SMA) and fibrotic disorders. The stock jump on November 14, 2025, was a direct result of the positive interim results from the Phase 3 study for the main drug Apicifermin for the treatment of Type 2 and Type 3 SMA. Apicifermin aims to improve...